Some early studies suggested a class of diabetes drugs called GLP-1 agonists, which have been proven to also help people lose weight and reduce…
What if reducing your dementia risk could be as simple as owning a dog? Several observational studies published last year suggest pet ownership could…
Medicare covers the cost of the anti-amyloid Alzheimer’s drug Leqembi, but many people with Alzheimer’s are under the age of 65 and don’t yet…
What will Alzheimer’s treatment look like in five years? At 2024’s Alzheimer’s Association International Conference in Philadelphia, experts provided a sneak peek into the…
During the Alzheimer’s Association International Conference in Philadelphia last week, researchers and drug companies presented data on a range of different Alzheimer’s drugs. Amidst…
According to new diagnostic criteria for Alzheimer’s, a blood test might be all you need to get diagnosed in the near future. At this…
On July 25th, European regulators said no to Eisai and Biogen’s anti-amyloid drug Leqembi for early stage Alzheimer’s. The European Medicines Agency (Europe’s version…
In a recent survey, Being Patient put a question to readers: “What is the biggest barrier preventing you from seeking a trial?” The most…
According to Homer Simpson, alcohol is “the cause of, and solution to, all of life’s problems.” While the patriarch of the Simpson family isn’t…
Dementia can be tough for young family members to get their heads around. Here are six pieces of guidance from children’s book authors who’ve…
By a woman’s late 40s, there is a good chance she’ll have started to experience the early phases of menopause. Menopause isn’t just the…
There are more than 500 active clinical trials for Alzheimer’s and other dementias in the U.S. They are designed to test different interventions, such…
Clinical trials and studies scientific experiments that investigate new treatments, lifestyle interventions, or risk factors for developing a disease like Alzheimer’s or dementia. By…
UPDATED JULY 3: The Food and Drug Administration has approved Kisunla (generic name donanemab), a new Alzheimer’s drug developed by Eli Lilly. The published data…
A new anti-amyloid drug for Alzheimer’s disease might receive FDA approval as soon as this month. Although anti-amyloid drugs have shown us that clear…